Drug intelligence / Profile preview

DS-Cav1

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DS-Cav1 is a stabilized prefusion RSV F subunit protein vaccine developed for the prevention of Respiratory Syncytial Virus (RSV) infections. It contains the RSV A2 fusion glycoprotein ectodomain assembled as a prefusion-stabilized trimer and has been tested both alone and with aluminum hydroxide adjuvant. Clinical trials have shown it elicits robust neutralizing antibody responses that remain elevated for at least 44 weeks after vaccination.

Other names: RSV prefusion F protein vaccinestabilized prefusion RSV F subunit proteinVRC 317VRC317VRC-317

Targets

RSV preF (Respiratory syncytial virus prefusion F glycoprotein)

Beyond the preview

Go deeper on DS-Cav1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-Cav1.

Explore the full profile